Q-omics provides the consensus-scored TRIM62 profile across patient tissues and cancer cell-line models. TRIM62 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TRIM62 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, TRIM62 RNA expression shows 20,336 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, LIHC, and ACC as cancer lineages where TRIM62 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM62 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM62 survival associations across molecular data types. TRIM62 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM62 RNA expression–survival associations across cancer types. High TRIM62 expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in SCLC, BLCA and LUAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for TRIM62 RNA expression.
This table summarizes TRIM62 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM62. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM62 shows lower tumor expression in KICH and higher tumor expression in LIHC, LUSC, BRCA, LUAD and CHOL. The LIHC box plot shows higher TRIM62 RNA expression in tumor versus normal tissue (log2 FC = +0.803, t-test p < 0.001).
This table shows molecular features associated with TRIM62 in patient tissues and cancer cell lines. In patient samples, TRIM62 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM62 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
